Several other analysts also recently commented on the stock. BidaskClub downgraded shares of Tesaro from a sell rating to a strong sell rating in a research report on Friday, April 20th. HC Wainwright reiterated a buy rating and issued a $108.00 price target on shares of Tesaro in a report on Tuesday, March 27th. ValuEngine upgraded shares of Tesaro from a sell rating to a hold rating in a report on Friday, March 2nd. Morgan Stanley reduced their price target on shares of Tesaro from $156.00 to $146.00 and set an overweight rating on the stock in a report on Thursday, March 1st. Finally, Credit Suisse Group reiterated an in-line rating and issued a $141.00 price target (down from $150.00) on shares of Tesaro in a report on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $128.26.
Shares of TSRO stock opened at $51.78 on Friday. The firm has a market cap of $2,848.59, a PE ratio of -5.65 and a beta of 1.34. Tesaro has a one year low of $50.67 and a one year high of $168.92. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74.
In other Tesaro news, CEO Leon O. Moulder, Jr. acquired 5,000 shares of the company’s stock in a transaction on Friday, March 2nd. The stock was acquired at an average cost of $56.93 per share, with a total value of $284,650.00. Following the purchase, the chief executive officer now directly owns 1,018,828 shares of the company’s stock, valued at approximately $58,001,878.04. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Orlando Oliveira sold 3,000 shares of Tesaro stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $69.88, for a total transaction of $209,640.00. Following the completion of the transaction, the senior vice president now directly owns 9,076 shares of the company’s stock, valued at $634,230.88. The disclosure for this sale can be found here. Over the last three months, insiders acquired 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. Company insiders own 33.70% of the company’s stock.
Several large investors have recently modified their holdings of TSRO. Bank of Montreal Can grew its stake in shares of Tesaro by 27.2% in the 4th quarter. Bank of Montreal Can now owns 9,103 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 1,948 shares in the last quarter. Gateway Investment Advisers LLC boosted its stake in shares of Tesaro by 30.2% during the 4th quarter. Gateway Investment Advisers LLC now owns 25,937 shares of the biopharmaceutical company’s stock worth $2,149,000 after purchasing an additional 6,016 shares during the period. Creative Planning boosted its stake in shares of Tesaro by 23.1% during the 4th quarter. Creative Planning now owns 50,209 shares of the biopharmaceutical company’s stock worth $4,161,000 after purchasing an additional 9,432 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Tesaro during the 4th quarter worth about $218,000. Finally, State of Alaska Department of Revenue purchased a new position in shares of Tesaro during the 4th quarter worth about $223,000.
TRADEMARK VIOLATION WARNING: This news story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://stocknewstimes.com/2018/04/26/tesaro-tsro-given-a-120-00-price-target-by-lake-street-capital-analysts.html.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.